This store requires javascript to be enabled for some features to work correctly.

Welcome Dream Team Aktion!

  • Cannabinoide

Wie wirken Cannabinoide?

The National Academies of Sciences. Engineering, Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research.Washington, DC: The National Academies Press; 2017.

WHO Expert Committee on Drug Dependence : CANNABIDIOL (CBD) Critical Review Report. Geneva: World Health Organization; 2018.

Whiting, Penny F et al. “Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.” JAMA vol. 313,24 (2015): 2456-73.

Bolognini, D et al. “Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation.” British journal of pharmacology vol. 168,6 (2013): 1456-70. 

Rock, Erin M et al. “Effect of cannabidiolic acid and ∆9-tetrahydrocannabinol on carrageenan-induced hyperalgesia and edema in a rodent model of inflammatory pain.” Psychopharmacology vol. 235,11 (2018): 3259-3271. 

van Breemen, Richard B et al. “Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants.” Journal of natural products vol. 85,1 (2022): 176-184.

Whiting, Penny F et al. “Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.” JAMA vol. 313,24 (2015): 2456-73. 

Plasse, T F. “Clinical use of dronabinol.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 9,11 (1991): 2079-80. 

Wang, Tongtong et al. “Adverse effects of medical cannabinoids: a systematic review.” CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne vol. 178,13 (2008): 1669-78. 

Nadal, Xavier et al. “Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity.” British journal of pharmacology vol. 174,23 (2017): 4263-4276. 

Moreno-Sanz, Guillermo. “Can You Pass the Acid Test? Critical Review and Novel Therapeutic Perspectives of Δ9-Tetrahydrocannabinolic Acid A.” Cannabis and cannabinoid research vol. 1,1 124-130. 1 Jun. 2016.

Wargent, E T et al. “The cannabinoid Δ(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity.” Nutrition & diabetes vol. 3,5 e68. 27 May 2013.

García, C et al. “Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease.” British journal of pharmacology vol. 163,7 (2011): 1495-506.

Navarro, Gemma et al. “Cannabigerol Action at Cannabinoid CB1 and CB2 Receptors and at CB1-CB2 Heteroreceptor Complexes.” Frontiers in pharmacology vol. 9 632. 21 Jun. 2018.

Borrelli, Francesca et al. “Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease.” Biochemical pharmacology vol. 85,9 (2013): 1306-16. 

Valdeolivas, Sara et al. “Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice.” Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics vol. 12,1 (2015): 185-99. 

Pagano, Ester et al. “Effect of Non-psychotropic Plant-derived Cannabinoids on Bladder Contractility: Focus on Cannabigerol.” Natural product communications vol. 10,6 (2015): 1009-12.

Colasanti, B K. “A comparison of the ocular and central effects of delta 9-tetrahydrocannabinol and cannabigerol.” Journal of ocular pharmacology vol. 6,4 (1990): 259-69. 

Brierley, Daniel I et al. “Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats.” Psychopharmacology vol. 233,19-20 (2016): 3603-13. 

Borrelli, Francesca et al. “Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid.” Carcinogenesis vol. 35,12 (2014): 2787-97. 

Appendino, Giovanni et al. “Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.” Journal of natural products vol. 71,8 (2008): 1427-30. 

Schier, Alexandre Rafael de Mello et al. “Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.” Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) vol. 34 Suppl 1 (2012): S104-10. 

Weydt, Patrick et al. “Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival.” Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases vol. 6,3 (2005): 182-4. 

Elsohly, M A et al. “Cannabinoids in glaucoma: a primary screening procedure.” Journal of clinical pharmacology vol. 21,S1 (1981): 472S-478S. 

Farrimond, Jonathan A et al. “Cannabinol and cannabidiol exert opposing effects on rat feeding patterns.” Psychopharmacology vol. 223,1 (2012): 117-29. 

Maione, Sabatino et al. “Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action.” British journal of pharmacology vol. 162,3 (2011): 584-96. 

Russo, Ethan B. “Cannabinoids in the management of difficult to treat pain.” Therapeutics and clinical risk management vol. 4,1 (2008): 245-59. 

DeLong, Gerald T et al. “Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol.” Drug and alcohol dependence vol. 112,1-2 (2010): 126-33. 

DeLong, Gerald T et al. “Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol.” Drug and alcohol dependence vol. 112,1-2 (2010): 126-33. 

Turner, C E, and M A Elsohly. “Biological activity of cannabichromene, its homologs and isomers.” Journal of clinical pharmacology vol. 21,S1 (1981): 283S-291S. 

El-Alfy, Abir T et al. “Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L.” Pharmacology, biochemistry, and behavior vol. 95,4 (2010): 434-42. 

Picardi, P et al. “Anandamide inhibits breast tumor-induced angiogenesis.” Translational medicine @ UniSa vol. 10 8-12. 8 Apr. 2014.

Morales, Paula et al. “Molecular Targets of the Phytocannabinoids: A Complex Picture.” Progress in the chemistry of organic natural products vol. 103 (2017): 103-131. 

Vree, T B et al. “Identification of cannabicyclol with a pentyl or propyl side-chain by means of combined gas chromatography-mass spectrometry.” Journal of chromatography vol. 74,1 (1972): 124-7.

Iannotti, Fabio Arturo et al. “Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability.” ACS chemical neuroscience vol. 5,11 (2014): 1131-41. 

Hill, T D M et al. “Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism.” British journal of pharmacology vol. 170,3 (2013): 679-92. 

Rock, Erin M et al. “Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats.” British journal of pharmacology vol. 170,3 (2013): 671-8. 

Pretzsch, Charlotte M et al. “Effects of cannabidivarin (CBDV) on brain excitation and inhibition systems in adults with and without Autism Spectrum Disorder (ASD): a single dose trial during magnetic resonance spectroscopy.” Translational psychiatry vol. 9,1 313. 20 Nov. 2019.

Vigli, Daniele et al. “Chronic treatment with the phytocannabinoid Cannabidivarin (CBDV) rescues behavioural alterations and brain atrophy in a mouse model of Rett syndrome.” Neuropharmacology vol. 140 (2018): 121-129.